Among the three applications of platelet rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and autologous fat concentration), PRP has the greatest market potential for current and future treatments. Bone marrow aspirate concentrate (BMAC) represents the next greatest market potential, followed by autologous fat concentration.
This assessment is based on a study of current market participants (total quantity of providers within on a global basis) and clinical trial rates worldwide.
Platelet-rich plasma (PRP) therapy is blood plasma that has been enriched with platelets, using a process of whole blood collection, followed by anticoagulation and centrifugation. This process separates the platelet-rich plasma (PRP) component of the blood from the red blood cells and other non-therapeutic components, producing a concentrated source of autologous (“self derived”) platelets as the final PRP product.
This resulting PRP component contains growth factors and cytokines that may have ability to support healing of bone, as well as soft tissue structures, including tendons, ligaments, and fascia. While there have not yet been large-scale, controlled clinical trials to evaluate the efficacy of PRP, the procedure has become commonplace in medical offices worldwide, most frequently within orthopedic offices
To date, PRP has been used as a clinical tool for several types of medical treatments, including orthopedics indications, plastic surgery applications, cosmetic applications, and aesthetic techniques.
With regard to orthopedic applications, PRP is most suitable for treatment of the:
PRP is most widely used for treatment of acute or chronic soft tissue injuries, acute and chronic ligamentous injuries, tendonitis, tennis elbow, de Quervains syndroms, Achilles tendonitis, plantar fasciitis and patellar tendonitis.1
In the plastic surgery field, PRP treatment is applied primarily for facial aesthetics, and it is used as a substitute for dermal fillers. Another developing application is hair re-growth, but here more evidence is needed to determine the effectiveness of PRP. There have been no high quality studies nor RCT-studies published with regard to the relationship between hair growth and PRP until recently.2
BMAC usage is limited at this time, but certainly expanding. There exist only a few clinical trials focused on this treatment, for example, limb ischemia, congestive heart failure, and osteonecrosis.3
Within the cosmetic field, the technique of autologous fat transplantation has attracted substantial interest from breast augmentation specialists.4 In addition, autologous fat transplantation is used in facial and body aesthetic treatments, including lip enlargement, flushing out hollow cheeks, chin enlargement, fat grafting to the hands, and fat transfer to the buttocks.
Geographically, patient applications for these three cell-based applications are most common within the United States, South America (particularly autologous fat concentration), and within larger European markets, such as the United Kingdom, Germany, Italy, France, and Spain.5
Because of the growing demand and relatively high costs of treatment within Western European countries, there are an increasing number of facilities opening within Eastern Europe where the providers are choosing to compete on price. Consequently, cost-conscious clients within Western Europe are now traveling to get treated at lower costs within these Eastern European facilities (i.e. medical tourism).
To learn more about the market for cell-based therapies, subscribe below.
BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
1 Orthopaedic Opinion Online: http://www.orthopaedicopiniononline.co.uk/index.php?id=359. Accessed Jan 16, 2016.
2 Glofinn Oy:.http://www.glofinn.com/applications/hair-loss/. Accessed Jan 17, 2016.
3 ClinicalTrials.gov: https://clinicaltrials.gov. Accessed Jan 15, 2016.
4 Fa-Cheng Li et al. Breast Augmentation With Autologous Fat Injection. Ann Plast Surg. 2014 Sep; 73(1):37–42.
5 Transparency Market Research: http://www.transparencymarketresearch.com/pressrelease/europe-platelet-rich-plasma-market.htm. Accessed Jan 16, 2016.